Royalty Pharma (RPRX) FCF Payout Ratio (2019 - 2026)

Royalty Pharma has disclosed FCF Payout Ratio across 8 years of filings, most recently posting 0.15 for Q1 2026.

• FCF Payout Ratio for Q1 2026 came in at 0.15, up 65.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.33 (down 36.88% YoY), and the FY2025 annual result was 0.21, down 55.52% from the prior year.
• FCF Payout Ratio came in at 0.15 for Q1 2026 at Royalty Pharma, down from 0.44 in the prior quarter.
• In the past five years, FCF Payout Ratio ranged from a high of 0.44 in Q4 2025 to a low of 0.44 in Q2 2024.
• The 5-year median for FCF Payout Ratio is 0.08 (2023), against an average of 0.05.
• Across the five-year window, FCF Payout Ratio surged 611.91% in 2023 and slumped 881.2% in 2024, its largest moves.
• Royalty Pharma's FCF Payout Ratio stood at 0.1 in 2022, then tumbled by 202.85% to 0.11 in 2023, then jumped by 219.81% to 0.13 in 2024, then soared by 241.26% to 0.44 in 2025, then sank by 65.6% to 0.15 in 2026.
• The last three FCF Payout Ratio figures came in at 0.15 (Q1 2026), 0.44 (Q4 2025), and 0.13 (Q3 2025), per Business Quant data.